No evidence of in vitro and in vivo porcine endogenous retrovirus infection after plasmapheresis through the AMC-bioartificial liver

Giuseppe Di Nicuolo, Maarten Paul Van De Kerkhove, Ruurdtje Hoekstra, Marcel G H M Beld, Pietro Amoroso, Sonia Battisti, Maria Starace, Ernesto Di Florio, Vincenzo Scuderi, Simona Scala, Adele Bracco, Antonio Mancini, Robert A F M Chamuleau, Fulvio Calise

Research output: Contribution to journalArticle

Abstract

Background: Currently a number of bioartificial livers (BAL) based on porcine liver cells have been developed as a treatment to bridge acute liver failure patients to orthotopic liver transplantation or liver regeneration. These Xenotransplantation related treatments hold the risk of infection of treated patients by porcine endogenous retrovirus (PERV) released from the porcine cells, as in vitro infection experiments and transplantations in immunocompromised mice have shown that PERV is able to infect human cells. The Academic Medical Center (AMC)-BAL, unlike other BALs, is characterized by direct contact between porcine liver cells and human plasma, and might therefore be permissive for PERV transfer. Methods: Prior to a clinical phase I trial, human plasma perfused through the AMC-BAL was investigated for PERV DNA and RNA. Moreover productive infectivity was analyzed by exposing the plasma to HEK-293 cells that were subsequently tested for PERV DNA, PERV RNA and reverse transcriptase activity. Results: Although PERV DNA was detected in the perfused plasma, no productive infectivity was detected. Consequently fourteen patients were treated with the AMC-BAL and monitored for PERV transmission. Immediately after treatment the plasma of the patients was positive for PERV DNA, most probably due to porcine liver cell lysis. The PERV DNA was cleared within 2 weeks post-treatment and no PERV RNA was detected. No productive infectivity in human embryonic kidney (HEK)-293 cells exposed to plasma of treated patients was detectable. Conclusion: To conclude, no release of infective PERV particles from the AMC-BAL was observed. Therefore we consider the AMC-BAL as safe, however careful surveillance of patients will be continued.

Original languageEnglish
Pages (from-to)286-292
Number of pages7
JournalXenotransplantation
Volume12
Issue number4
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Retroviridae Infections
Artificial Liver
Endogenous Retroviruses
Plasmapheresis
Swine
DNA
In Vitro Techniques
RNA-Directed DNA Polymerase
Liver
RNA
Kidney
Dimercaprol
Heterologous Transplantation
Clinical Trials, Phase I
Liver Regeneration

Keywords

  • Bioartificial liver
  • Hepatocytes
  • Liver failure
  • PERV
  • Pig
  • Xenotransplantation

ASJC Scopus subject areas

  • Immunology

Cite this

Di Nicuolo, G., Van De Kerkhove, M. P., Hoekstra, R., Beld, M. G. H. M., Amoroso, P., Battisti, S., ... Calise, F. (2005). No evidence of in vitro and in vivo porcine endogenous retrovirus infection after plasmapheresis through the AMC-bioartificial liver. Xenotransplantation, 12(4), 286-292. https://doi.org/10.1111/j.1399-3089.2005.00226.x

No evidence of in vitro and in vivo porcine endogenous retrovirus infection after plasmapheresis through the AMC-bioartificial liver. / Di Nicuolo, Giuseppe; Van De Kerkhove, Maarten Paul; Hoekstra, Ruurdtje; Beld, Marcel G H M; Amoroso, Pietro; Battisti, Sonia; Starace, Maria; Di Florio, Ernesto; Scuderi, Vincenzo; Scala, Simona; Bracco, Adele; Mancini, Antonio; Chamuleau, Robert A F M; Calise, Fulvio.

In: Xenotransplantation, Vol. 12, No. 4, 07.2005, p. 286-292.

Research output: Contribution to journalArticle

Di Nicuolo, G, Van De Kerkhove, MP, Hoekstra, R, Beld, MGHM, Amoroso, P, Battisti, S, Starace, M, Di Florio, E, Scuderi, V, Scala, S, Bracco, A, Mancini, A, Chamuleau, RAFM & Calise, F 2005, 'No evidence of in vitro and in vivo porcine endogenous retrovirus infection after plasmapheresis through the AMC-bioartificial liver', Xenotransplantation, vol. 12, no. 4, pp. 286-292. https://doi.org/10.1111/j.1399-3089.2005.00226.x
Di Nicuolo, Giuseppe ; Van De Kerkhove, Maarten Paul ; Hoekstra, Ruurdtje ; Beld, Marcel G H M ; Amoroso, Pietro ; Battisti, Sonia ; Starace, Maria ; Di Florio, Ernesto ; Scuderi, Vincenzo ; Scala, Simona ; Bracco, Adele ; Mancini, Antonio ; Chamuleau, Robert A F M ; Calise, Fulvio. / No evidence of in vitro and in vivo porcine endogenous retrovirus infection after plasmapheresis through the AMC-bioartificial liver. In: Xenotransplantation. 2005 ; Vol. 12, No. 4. pp. 286-292.
@article{5cb9ecd0b7794e97b6cd928bacde77e6,
title = "No evidence of in vitro and in vivo porcine endogenous retrovirus infection after plasmapheresis through the AMC-bioartificial liver",
abstract = "Background: Currently a number of bioartificial livers (BAL) based on porcine liver cells have been developed as a treatment to bridge acute liver failure patients to orthotopic liver transplantation or liver regeneration. These Xenotransplantation related treatments hold the risk of infection of treated patients by porcine endogenous retrovirus (PERV) released from the porcine cells, as in vitro infection experiments and transplantations in immunocompromised mice have shown that PERV is able to infect human cells. The Academic Medical Center (AMC)-BAL, unlike other BALs, is characterized by direct contact between porcine liver cells and human plasma, and might therefore be permissive for PERV transfer. Methods: Prior to a clinical phase I trial, human plasma perfused through the AMC-BAL was investigated for PERV DNA and RNA. Moreover productive infectivity was analyzed by exposing the plasma to HEK-293 cells that were subsequently tested for PERV DNA, PERV RNA and reverse transcriptase activity. Results: Although PERV DNA was detected in the perfused plasma, no productive infectivity was detected. Consequently fourteen patients were treated with the AMC-BAL and monitored for PERV transmission. Immediately after treatment the plasma of the patients was positive for PERV DNA, most probably due to porcine liver cell lysis. The PERV DNA was cleared within 2 weeks post-treatment and no PERV RNA was detected. No productive infectivity in human embryonic kidney (HEK)-293 cells exposed to plasma of treated patients was detectable. Conclusion: To conclude, no release of infective PERV particles from the AMC-BAL was observed. Therefore we consider the AMC-BAL as safe, however careful surveillance of patients will be continued.",
keywords = "Bioartificial liver, Hepatocytes, Liver failure, PERV, Pig, Xenotransplantation",
author = "{Di Nicuolo}, Giuseppe and {Van De Kerkhove}, {Maarten Paul} and Ruurdtje Hoekstra and Beld, {Marcel G H M} and Pietro Amoroso and Sonia Battisti and Maria Starace and {Di Florio}, Ernesto and Vincenzo Scuderi and Simona Scala and Adele Bracco and Antonio Mancini and Chamuleau, {Robert A F M} and Fulvio Calise",
year = "2005",
month = "7",
doi = "10.1111/j.1399-3089.2005.00226.x",
language = "English",
volume = "12",
pages = "286--292",
journal = "Xenotransplantation",
issn = "0908-665X",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - No evidence of in vitro and in vivo porcine endogenous retrovirus infection after plasmapheresis through the AMC-bioartificial liver

AU - Di Nicuolo, Giuseppe

AU - Van De Kerkhove, Maarten Paul

AU - Hoekstra, Ruurdtje

AU - Beld, Marcel G H M

AU - Amoroso, Pietro

AU - Battisti, Sonia

AU - Starace, Maria

AU - Di Florio, Ernesto

AU - Scuderi, Vincenzo

AU - Scala, Simona

AU - Bracco, Adele

AU - Mancini, Antonio

AU - Chamuleau, Robert A F M

AU - Calise, Fulvio

PY - 2005/7

Y1 - 2005/7

N2 - Background: Currently a number of bioartificial livers (BAL) based on porcine liver cells have been developed as a treatment to bridge acute liver failure patients to orthotopic liver transplantation or liver regeneration. These Xenotransplantation related treatments hold the risk of infection of treated patients by porcine endogenous retrovirus (PERV) released from the porcine cells, as in vitro infection experiments and transplantations in immunocompromised mice have shown that PERV is able to infect human cells. The Academic Medical Center (AMC)-BAL, unlike other BALs, is characterized by direct contact between porcine liver cells and human plasma, and might therefore be permissive for PERV transfer. Methods: Prior to a clinical phase I trial, human plasma perfused through the AMC-BAL was investigated for PERV DNA and RNA. Moreover productive infectivity was analyzed by exposing the plasma to HEK-293 cells that were subsequently tested for PERV DNA, PERV RNA and reverse transcriptase activity. Results: Although PERV DNA was detected in the perfused plasma, no productive infectivity was detected. Consequently fourteen patients were treated with the AMC-BAL and monitored for PERV transmission. Immediately after treatment the plasma of the patients was positive for PERV DNA, most probably due to porcine liver cell lysis. The PERV DNA was cleared within 2 weeks post-treatment and no PERV RNA was detected. No productive infectivity in human embryonic kidney (HEK)-293 cells exposed to plasma of treated patients was detectable. Conclusion: To conclude, no release of infective PERV particles from the AMC-BAL was observed. Therefore we consider the AMC-BAL as safe, however careful surveillance of patients will be continued.

AB - Background: Currently a number of bioartificial livers (BAL) based on porcine liver cells have been developed as a treatment to bridge acute liver failure patients to orthotopic liver transplantation or liver regeneration. These Xenotransplantation related treatments hold the risk of infection of treated patients by porcine endogenous retrovirus (PERV) released from the porcine cells, as in vitro infection experiments and transplantations in immunocompromised mice have shown that PERV is able to infect human cells. The Academic Medical Center (AMC)-BAL, unlike other BALs, is characterized by direct contact between porcine liver cells and human plasma, and might therefore be permissive for PERV transfer. Methods: Prior to a clinical phase I trial, human plasma perfused through the AMC-BAL was investigated for PERV DNA and RNA. Moreover productive infectivity was analyzed by exposing the plasma to HEK-293 cells that were subsequently tested for PERV DNA, PERV RNA and reverse transcriptase activity. Results: Although PERV DNA was detected in the perfused plasma, no productive infectivity was detected. Consequently fourteen patients were treated with the AMC-BAL and monitored for PERV transmission. Immediately after treatment the plasma of the patients was positive for PERV DNA, most probably due to porcine liver cell lysis. The PERV DNA was cleared within 2 weeks post-treatment and no PERV RNA was detected. No productive infectivity in human embryonic kidney (HEK)-293 cells exposed to plasma of treated patients was detectable. Conclusion: To conclude, no release of infective PERV particles from the AMC-BAL was observed. Therefore we consider the AMC-BAL as safe, however careful surveillance of patients will be continued.

KW - Bioartificial liver

KW - Hepatocytes

KW - Liver failure

KW - PERV

KW - Pig

KW - Xenotransplantation

UR - http://www.scopus.com/inward/record.url?scp=20944450446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20944450446&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3089.2005.00226.x

DO - 10.1111/j.1399-3089.2005.00226.x

M3 - Article

C2 - 15943777

AN - SCOPUS:20944450446

VL - 12

SP - 286

EP - 292

JO - Xenotransplantation

JF - Xenotransplantation

SN - 0908-665X

IS - 4

ER -